<MedlineCitationSet>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11710680</PMID>
<DateCreated>
<Year>2001</Year>
<Month>11</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>2001</Year>
<Month>12</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0002-9173</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>116</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2001</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>American journal of clinical pathology</Title>
<ISOAbbreviation>Am. J. Clin. Pathol.</ISOAbbreviation>
</Journal>
<ArticleTitle>-- THIS DOCUMENT WILL BE OVERWRITTEN BY AN UPDATE DOCUMENT -- Prevalence and cellular reservoir of latent human herpesvirus 6 in tonsillar lymphoid tissue.</ArticleTitle>
<Pagination>
<MedlinePgn>648-54</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>-- THIS DOCUMENT WILL BE OVERWRITTEN BY AN UPDATE DOCUMENT -- There are few studies that examine prevalence, quantity, and cellular proclivity of latent human herpesvirus 6 (HHV-6) in healthy populations. We examined 69 tonsils with paired blood specimens from children without evidence of acute infection. By polymerase chain reaction (PCR), HHV-6 was detected at low levels in 100% of tonsils and 39% of blood samples (n = 27), suggesting that prevalence of latent HHV-6 infection is high in children and may be underestimated by PCR analysis of blood. Although HHV-6A and HHV-6B were detected, HHV-6B predominated, being found in 97% of samples (n = 67). Tonsil sections from 7 cases were examined by in situ hybridization using 2 HHV-6 probes and immunohistochemical analysis. Using both in situ hybridization and immunohistochemical analysis, all tissues revealed marked HHV-6-specific staining in the squamous epithelium of the tonsillar crypts and rare positive lymphocytes. We conclude that HHV-6 is present universally in tonsils of children, and tonsillar epithelium may be an important viral reservoir in latent infection.</AbstractText>
</Abstract>
<Affiliation>Department of Pathology, University of Texas Southwestern Medical Center at Dallas, USA.</Affiliation>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Roush</LastName>
<ForeName>K S</ForeName>
<Initials>KS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Domiati-Saad</LastName>
<ForeName>R K</ForeName>
<Initials>RK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Margraf</LastName>
<ForeName>L R</ForeName>
<Initials>LR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krisher</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scheuermann</LastName>
<ForeName>R H</ForeName>
<Initials>RH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rogers</LastName>
<ForeName>B B</ForeName>
<Initials>BB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dawson</LastName>
<ForeName>D B</ForeName>
<Initials>DB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Clin Pathol</MedlineTA>
<NlmUniqueID>0370470</NlmUniqueID>
<ISSNLinking>0002-9173</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>DNA Primers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>DNA, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Primers</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA, Viral</DescriptorName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Exanthema Subitum</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Herpesvirus 6, Human</DescriptorName>
<QualifierName MajorTopicYN="N">classification</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">In Situ Hybridization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Palatine Tonsil</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12132614</PMID>
<DateCreated>
<Year>2002</Year>
<Month>07</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted>
<Year>2003</Year>
<Month>01</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>02</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0365-5237</ISSN>
<JournalIssue CitedMedium="Print">
<Issue>546</Issue>
<PubDate>
<Year>2002</Year>
</PubDate>
</JournalIssue>
<Title>Acta oto-laryngologica. Supplementum</Title>
<ISOAbbreviation>Acta Otolaryngol Suppl</ISOAbbreviation>
</Journal>
<ArticleTitle>-- THIS DOCUMENT WILL BE DELETED -- A case of Cronkhite-Canada syndrome whose major complaint, taste disturbance, was improved by zinc therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>154-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>-- THIS DOCUMENT WILL BE DELETED -- A patient whose major complaint was taste disturbance and who was diagnosed as having Cronkhite-Canada syndrome was prescribed zinc sulfate. Improvement in taste disturbance was noted after 3 weeks of treatment, followed by gradual improvement in skin and gastrointestinal symptoms. Cronkhite-Canada syndrome can be considered a zinc-deficiency disorder caused by gastrointestinal polyposis.</AbstractText>
</Abstract>
<Affiliation>Department of Otolaryngology, Nihon University School of Medicine, Tokyo, Japan.</Affiliation>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yoshida</LastName>
<ForeName>Shinya</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tomita</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Norway</Country>
<MedlineTA>Acta Otolaryngol Suppl</MedlineTA>
<NlmUniqueID>0370355</NlmUniqueID>
<ISSNLinking>0365-5237</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>7440-66-6</RegistryNumber>
<NameOfSubstance>Zinc</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chorda Tympani Nerve</DescriptorName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electrophysiology</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Glossopharyngeal Nerve</DescriptorName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Intestinal Polyps</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Taste Disorders</DescriptorName>
<QualifierName MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zinc</DescriptorName>
<QualifierName MajorTopicYN="N">deficiency</QualifierName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
 <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22551777</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>08</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>01</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5462</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gene therapy</Title>
                <ISOAbbreviation>Gene Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>-- THIS DOCUMENT IS INSERTED ONCE AND THEN LEFT UNTOUCHED (neither deleted nor replaced by an update documents) --Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.</ArticleTitle>
            <Pagination>
                <MedlinePgn>872-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/gt.2012.37</ELocationID>
            <Abstract>
                <AbstractText>-- THIS DOCUMENT IS INSERTED ONCE AND THEN LEFT UNTOUCHED (neither deleted nor replaced by an update documents) -- Patients with X-linked severe combined immunodeficiency (SCID-X1) were successfully cured following gene therapy with a gamma-retroviral vector (gRV) expressing the common gamma chain of the interleukin-2 receptor (IL2RG). However, 5 of 20 patients developed leukemia from activation of cellular proto-oncogenes by viral enhancers in the long-terminal repeats (LTR) of the integrated vector. These events prompted the design of a gRV vector with self-inactivating (SIN) LTRs to enhance vector safety. Herein we report on the production of a clinical-grade SIN IL2RG gRV pseudotyped with the Gibbon Ape Leukemia Virus envelope for a new gene therapy trial for SCID-X1, and highlight variables that were found to be critical for transfection-based large-scale SIN gRV production. Successful clinical production required careful selection of culture medium without pre-added glutamine, reduced exposure of packaging cells to cell-dissociation enzyme, and presence of cations in wash buffer. The clinical vector was high titer; transduced 68-70% normal human CD34(+) cells, as determined by colony-forming unit assays and by xenotransplantation in immunodeficient NOD.CB17-Prkdc(scid)/J (nonobese diabetic/severe combined immunodeficiency (NOD/SCID)) and NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ (NOD/SCID gamma (NSG))) mice; and resulted in the production of T cells in vitro from human SCID-X1 CD34(+) cells. The vector was certified and released for the treatment of SCID-X1 in a multi-center international phase I/II trial.</AbstractText>
            </Abstract>
            <Affiliation>Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA. Han.vanderloo@cchmc.org</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van der Loo</LastName>
                    <ForeName>J C M</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swaney</LastName>
                    <ForeName>W P</ForeName>
                    <Initials>WP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grassman</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Terwilliger</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Higashimoto</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schambach</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hacein-Bey-Abina</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nordling</LastName>
                    <ForeName>D L</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cavazzana-Calvo</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thrasher</LastName>
                    <ForeName>A J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Williams</LastName>
                    <ForeName>D A</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reeves</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malik</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>UL1 TR000077</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>05</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Gene Ther</MedlineTA>
            <NlmUniqueID>9421525</NlmUniqueID>
            <ISSNLinking>0969-7128</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Interleukin Receptor Common gamma Subunit</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <SupplMeshList>
            <SupplMeshName Type="Disease">Severe combined immunodeficiency, X-linked</SupplMeshName>
        </SupplMeshList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Gene Transfer Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Genetic Vectors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Interleukin Receptor Common gamma Subunit</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukemia Virus, Gibbon Ape</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice, SCID</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Retroviridae</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Terminal Repeat Sequences</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Transduction, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">X-Linked Combined Immunodeficiency Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
</MedlineCitationSet>
